Weaver Consulting Group Amgen Inc Transaction History

Weaver Consulting Group

$264 Million
Q2 2024

A detailed history of Weaver Consulting Group transactions in Amgen Inc stock. As of the latest transaction made, Weaver Consulting Group holds 1,646 shares of AMGN stock, worth $547,212. This represents 0.19% of its overall portfolio holdings.

Number of Shares

1,646

Previous 1,646 -0.0%

Holding current value

$547,212

Previous $467,000 10.06%

% of portfolio

0.19%

Previous 0.18%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 16, 2024	SELL	$268.87 - $324.56 $26,887 - $32,456	-100 Reduced 5.73%	1,646 $467,000
Q4 2023 Jan 22, 2024	SELL	$255.7 - $288.46 $8,949 - $10,096	-35 Reduced 1.97%	1,746 $502,000
Q3 2023 Oct 13, 2023	BUY	$218.65 - $271.46 $21,865 - $27,145	100 Added 5.95%	1,781 $478,000
Q1 2023 Apr 11, 2023	SELL	$225.79 - $275.2 $19,643 - $23,942	-87 Reduced 4.92%	1,681 $406,000
Q2 2022 Jul 20, 2022	BUY	$230.71 - $256.74 $20,994 - $23,363	91 Added 5.43%	1,768 $430,000
Q1 2022 May 06, 2022	SELL	$219.27 - $242.57 $6,578 - $7,277	-30 Reduced 1.76%	1,677 $406,000
Q4 2021 Feb 01, 2022	BUY	$198.88 - $227.6 $20,882 - $23,898	105 Added 6.55%	1,707 $384,000
Q3 2021 Oct 28, 2021	BUY	$212.27 - $248.7 $9,552 - $11,191	45 Added 2.89%	1,602 $341,000
Q2 2021 Jul 06, 2021	BUY	$233.58 - $259.14 $76,847 - $85,257	329 Added 26.79%	1,557 $380,000
Q1 2021 Apr 07, 2021	SELL	$221.91 - $258.6 $7,101 - $8,275	-32 Reduced 2.54%	1,228 $306,000
Q3 2019 Nov 22, 2019	SELL	$174.11 - $208.62 $17,411 - $20,862	-100 Reduced 7.35%	1,260 $222,000
Q1 2019 Jun 19, 2019	BUY	$180.87 - $203.88 $245,983 - $277,276	1,360 New	1,360 $239,000

Others Institutions Holding AMGN

# of Institutions

3,054

Shares Held

409M

Call Options Held

7.19M

Put Options Held

6.26M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $178B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Weaver Consulting Group, based on Form 13F filings with the SEC.

News

Stay updated on Weaver Consulting Group with notifications on news.

Account

Weaver Consulting Group Amgen Inc Transaction History